The SP is stuck close to 6 cents for a week in anticipation of...

The SP is stuck close to 6 cents for a week in anticipation of June announcements which should come next week or hopefully Monday. Each day the SP goes down a couple of pips on almost no volume so your doji seems abit dodgy to me. The SP will fly if the announcement is good and vice versa. Everyone is waiting for the announcement. Get in before you miss out.

From the NDF research May 2018 update:

Where to from here? It seems that Patrys has positioned itself very well with the DX1 asset, and what was originally in-licensed as a discrete asset actually has the attributes of being an asset platform with multiple and varied applications. We expect that the rest of 2018 and much of 2019 will see a continued accrual of favourable data around both PAT-DX1 and PAT-DX1-NP. The various pre-clinical studies will likely guide the choice of initial clinical indications for both PAT-DX1 and PAT-DX1-NP in the second half of this year, after which the product can go into toxicology studies ahead of the commencement of clinical work from late 2019.

Clinical work means human trials from large 2019.

NDF: Our 13 cents per share price target remains unchanged. We previously valued Patrys at 7.3 cents per share base case and 18.3 cents optimistic case. With this note our valuation range changed to 6.3 cents base case and 14.7 cents optimistic case.

Re-rating Patrys

We see the following developments helping to continue re-rating Patrys towards our target price:

• - Initial production runs for PAT-DX1;
• - Further animal data from PAT-DX1;
• - Moves to take PAT-DX1 into the clinic, including an IND filing and filing for Orphan Drug Status.
  Happy New Year to all. Brainy